MedTrace Logo

Evaluating Simvastatin's Potential Role in Therapy

NCT00486044 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2019-03-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see how simvastatin, a cholesterol-lowering drug, affects processes related to the development of Alzheimer's disease, including: 1) levels of a substance called beta-amyloid-42 found in the spinal fluid surrounding the brain, 2) blood flow in the brain, 3) inflammation in the brain, and 4) cognitive function.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Simvastatin

40 mg tablet each night for one month, then 80 mg for 8 months

DRUG

Placebo

Matching tablet each night for 9 months

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Paul Beeson Faculty Scholars Program

    collaborator OTHER

  • The John A. Hartford Foundation

    collaborator OTHER

  • The Atlantic Philanthropies

    collaborator OTHER

  • Starr Foundation

    collaborator OTHER

  • American Federation for Aging Research

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Cynthia M. Carlsson, MD, MS · University of Wisconsin, Madison

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00486044 on ClinicalTrials.gov